Screener
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: ImmunityBio, Inc.’s 10-K, filed March 3, 2025.
- Filed
- Mar 3, 2025
- Fiscal year
- FY2024
- Accession
- 0001326110-25-000033
| Line item | Year Ended December 31, 2024 | Year Ended December 31, 2023 | Year Ended December 31, 2022 |
|---|---|---|---|
| Total revenue | 14,745 | 622 | 240 |
| Operating costs and expenses | |||
| Cost of sales | — | — | — |
| Research and development (including amounts with related parties) | 190,144 | 232,366 | 248,149 |
| Selling, general and administrative (including amounts with related parties) | 168,783 | 129,620 | 102,708 |
| Impairment of intangible assets | — | 886 | 681 |
| Total operating costs and expenses | 358,927 | 362,872 | 351,538 |
| Loss from operations | (344,182) | (362,250) | (351,298) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is ImmunityBio, Inc.'s R&D?
- ImmunityBio, Inc. (IBRX) reported R&D of $35.22M in Q4 2024.
- How has ImmunityBio, Inc.'s R&D changed year-over-year?
- ImmunityBio, Inc.'s R&D decreased by 31.7% year-over-year, from $51.53M to $35.22M.
- What is the long-term trend for ImmunityBio, Inc.'s R&D?
- Over 3 years (2021 to 2024), ImmunityBio, Inc.'s R&D has grown at a -1.0% compound annual growth rate (CAGR), from $195.96M to $190.14M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about ImmunityBio, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude